JPRN-jRCTs051180199
Recruiting
Phase 3
S1+ intravenous and intraperitoneal Paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis; Multicenter randomized phase III trial - S1+ intravenous and intraperitoneal Paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis; Multicenter randomized phase III trial
Satoi Sohei0 sites180 target enrollmentStarted: March 26, 2019Last updated:
ConditionsInvasive ductal adenocarcinoma
Overview
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Satoi Sohei
- Enrollment
- 180
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to < 80age old (—)
- Sex
- All
Inclusion Criteria
- •Patients with peritoneal metastasis without other organ metastases
Exclusion Criteria
- •Cytology positive in patients with resectable/borderiline resectable pancreatic ductal adenocarcinoma
Investigators
Similar Trials
Recruiting
Phase 2
Intraperitoneal and intravenous paclitaxel plus S-1Gastric cancer with peritoneal metastasis or positive peritoneal cytology.JPRN-jRCTs061180008Fujiwara Yoshiyuki50
Not yet recruiting
Not Applicable
Treatment of abdominal mesothelioma with intra-abdominal chemotherapy - INTERACT MESONL-OMON26729one21
Recruiting
Not Applicable
Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety StudyNL-OMON56619Erasmus MC, Universitair Medisch Centrum Rotterdam21
Not yet recruiting
Not Applicable
Phase 3 study of Paclitaxel therapy and monolithic systemic chemotherapy in patients with gastric cancer and gastroesophageal border cancer with peritoneal metastasisNeoplasmsKCT0009110Koera University Guro Hospital117
Completed
Phase 2
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000023000agoya University50